Colleen Kusy
Stock Analyst at Baird
(1.22)
# 3,655
Out of 5,067 analysts
53
Total ratings
34.78%
Success rate
-10.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $109.53 | +44.25% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $38.54 | -11.78% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $20.13 | +158.32% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $12.10 | +98.35% | 5 | Oct 3, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $9 | $1.77 | +409.92% | 1 | Aug 15, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $21.77 | +138.86% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $4.29 | +39.86% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $19.27 | +112.77% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.28 | +368.75% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $26.97 | +141.01% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $100 → $75 | $27.39 | +173.82% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $11.79 | +112.04% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $5.56 | +3,676.98% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.50 | +1,260.00% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $4.02 | +5,621.39% | 1 | Nov 2, 2021 |
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $109.53
Upside: +44.25%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $38.54
Upside: -11.78%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $20.13
Upside: +158.32%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $12.10
Upside: +98.35%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $1.77
Upside: +409.92%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $21.77
Upside: +138.86%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $4.29
Upside: +39.86%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $19.27
Upside: +112.77%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.28
Upside: +368.75%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $26.97
Upside: +141.01%
Aug 14, 2024
Maintains: Neutral
Price Target: $100 → $75
Current: $27.39
Upside: +173.82%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $11.79
Upside: +112.04%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $5.56
Upside: +3,676.98%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.50
Upside: +1,260.00%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $4.02
Upside: +5,621.39%